We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VRA:NASDAQVera Bradley, Inc. Analysis

Data as of 2026-05-09 - not real-time

$4.14

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Vera Bradley’s stock is trading at $4.14, comfortably above its 20‑day ($4.03), 50‑day ($3.53) and 200‑day ($2.64) simple moving averages, indicating a bullish price trend. The RSI of 61 supports continued upside momentum, though the MACD histogram is slightly negative, hinting at short‑term bearish pressure. Fundamentally, the market price is far below the DCF‑derived fair value of $15.04 and the price‑to‑book ratio of 0.88, suggesting a substantial valuation gap, while the price‑to‑sales of 0.44 reinforces a value‑oriented case. However, the company reports a –17.7% profit margin, negative EBITDA and a trailing EPS of –$1.17, with a forward EPS of only $0.01 and a forward P/E of 414, underscoring ongoing earnings challenges. The balance sheet shows $70.5M of debt versus $18.5M of cash (debt‑to‑equity ~53%), and free cash flow is positive at $36M, offering a modest cushion. Recent corporate actions – the early termination of the shareholder rights plan and the departure of board member Carrie Tharp – are material but do not directly address operational performance.
Given the high 30‑day volatility (≈60%) and a beta above 1, the stock is sensitive to market swings, yet the low multiples and sizable intrinsic‑value upside make it an attractive speculative play for investors willing to tolerate earnings risk while the company seeks a turnaround.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near recent resistance at $4.39
  • Negative MACD histogram indicating short‑term bearish pressure
  • Elevated volatility and beta increasing price swing risk

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF fair value ($15.04) far exceeds current price, implying upside
  • Low price‑to‑book (0.88) and price‑to‑sales (0.44) suggest deep value
  • Positive free cash flow provides a buffer for restructuring

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Potential earnings recovery from turnaround initiatives
  • Debt level manageable relative to cash and asset base
  • Consumer‑cyclical positioning could benefit from post‑recession spending

Key Metrics & Analysis

Financial Health

Revenue Growth-1.70%
Profit Margin-17.74%
P/E Ratio414.0
ROE-21.04%
ROA-6.34%
Debt/Equity53.58
P/B Ratio0.9
Op. Cash Flow$-9971000
Free Cash Flow$36.0M

Technical Analysis

TrendBullish
RSI61.4
Support$3.65
Resistance$4.39
MA 20$4.03
MA 50$3.53
MA 200$2.64
MACDBearish
VolumeStable
Fear & Greed Index90.73

Valuation

Fair Value$15.04
GradeUndervalued
TypeValue

Risk Assessment

Beta1.20
Volatility60.26%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.